Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03190915 2026-04-13

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Phase 2 Active not recruiting

10 enrolled 11 charts

CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT03919071 2026-04-13

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Phase 2 Active not recruiting

58 enrolled

CNS

Astrocytoma, Glioblastoma, Glioma

NCT04439292 2026-04-13

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Phase 2 Active not recruiting

35 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439318 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

Phase 2 Active not recruiting

50 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439357 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Phase 2 Active not recruiting

4 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04485559 2026-04-13

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Phase 1 Suspended

50 enrolled

CNS

Glioma

NCT05518110 2026-04-13

PaTcH

Phase 2 Terminated

20 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03975231 2026-04-08

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Phase 1 Recruiting

6 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT04892017 2026-04-08

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Phase 1 Terminated

91 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02693535 2026-04-02

TAPUR

Phase 2 Recruiting

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03975829 2026-04-02

Pediatric Long-Term Follow-up and Rollover Study

Phase 4 Active not recruiting

163 enrolled

CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT04557956 2026-04-02

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Phase 1/2 Active not recruiting

16 enrolled

Dermatologic

Melanoma

NCT07468071 2026-04-02

KontRASt-R

Phase 1/2 Not yet recruiting

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03340506 2026-04-01

Dabrafenib and/or Trametinib Rollover Study

Phase 4 Recruiting

100 enrolled

CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

1,500 enrolled

Tumor-Agnostic

Neoplasms

NCT03244956 2026-03-23

MERAIODE

Phase 2 Completed

40 enrolled

EndocrineHead & Neck

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

NCT06475989 2026-03-23

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Phase 3 Recruiting

264 enrolled

Head & Neck

Refractory Differentiated Thyroid Gland Carcinoma

NCT06804824 2026-03-18

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

220 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Phase 2 Recruiting

45 enrolled

Sarcoma

Neoplasm Metastasis, Osteosarcoma

NCT03091257 2026-03-13

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Active not recruiting

30 enrolled

Plasma cell

Multiple Myeloma

NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Phase 2 Active not recruiting

134 enrolled

Dermatologic

Melanoma

NCT02642042 2026-03-04

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Phase 2 Active not recruiting

60 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02645149 2026-02-27

Match Mel

Phase 2 Completed

216 enrolled

Dermatologic

Melanoma

NCT03501368 2026-02-27

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Phase 1 Completed

27 enrolled

Dermatologic

Melanoma

NCT05907304 2026-02-27

SEACRAFT-1

Phase 1 Active not recruiting

86 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT06346067 2026-02-27

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Phase 3 Active not recruiting

78 enrolled

Dermatologic

Melanoma

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

30 enrolled

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT04666272 2026-02-19